Skip to content
Evigrade
MajorAntiinflammatory and antirheumatic agents, non-steroids. Other NSAIDs×Calcineurin inhibitor (immunosuppressant)

Updated · Methodology

Mechanism

Tacrolimus can impair renal function on its own. Drugs with known nephrotoxic or neurotoxic effects, including non-steroidal anti-inflammatory drugs (NSAIDs), may potentiate these effects of tacrolimus (tacrolimus summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Nimesulide is an NSAID that inhibits cyclo-oxygenase, the enzyme that synthesises prostaglandins (harmonised EU SmPC for nimesulide, European Medicines Agency, EMA). This SmPC states that prostaglandin synthetase inhibitors such as nimesulide may increase the nephrotoxicity of ciclosporin through their effect on renal prostaglandins. It says nothing about tacrolimus (EMA). Tacrolimus is more than 98.8% bound to plasma proteins and nimesulide up to 97.5%. The tacrolimus SmPC asks prescribers to consider possible interactions with other highly protein-bound drugs, including NSAIDs (AEMPS).

Symptoms

Tacrolimus very commonly impairs renal function and causes hyperkalaemia. Common reactions include oliguria and renal failure, including acute renal failure (tacrolimus summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acute renal impairment from tacrolimus toxicity can show as high serum creatinine, hyperkalaemia, reduced urea excretion and hyperuricaemia, and is usually reversible (tacrolimus label, US Food and Drug Administration, FDA). In renal or cardiac impairment, nimesulide may worsen renal function. Its rare adverse reactions include hyperkalaemia, dysuria, haematuria and urinary retention. Very rare ones include renal failure, oliguria and interstitial nephritis (harmonised EU SmPC for nimesulide, European Medicines Agency, EMA).

Management

The combination is not contraindicated. The tacrolimus summary of product characteristics (SmPC) recommends avoiding tacrolimus with drugs that have known nephrotoxic effects and explicitly lists non-steroidal anti-inflammatory drugs (NSAIDs) among them. Nimesulide belongs to this class (tacrolimus SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If the combination cannot be avoided, closely monitor tacrolimus trough blood levels, renal function and other adverse effects. Adjust the tacrolimus dose if needed, and consider reducing it if nephrotoxicity occurs (AEMPS). The US tacrolimus label says to monitor renal function and tacrolimus blood levels when tacrolimus is combined with other known nephrotoxic drugs. During concurrent use, adjust the dose of tacrolimus, the other drug or both (tacrolimus label, US Food and Drug Administration, FDA). Nimesulide is contraindicated in severe renal impairment (creatinine clearance below 30 mL/min). In renal or cardiac impairment, use it with caution and stop it if renal function deteriorates. Keep the course as short as possible (harmonised EU SmPC for nimesulide, European Medicines Agency, EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Nimesulide

Other interactions with Tacrolimus